OrphAI Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 16

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $56.9M

OrphAI Therapeutics General Information

Description

Developer of a precision therapeutics technology designed to treat cancer and rare diseases. The company's technology accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics and combinational drug screening with deep learning to match clinical drugs, enabling doctors to treat diseases by providing significant therapeutic benefits for patients.

Contact Information

Formerly Known As
LAM Therapeutics, AI Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OrphAI Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 18-May-2026 $56.9M Completed Clinical Trials - Phase 2
6. Later Stage VC (Series E) 11-Oct-2024 Completed Clinical Trials - Phase 2
5. Debt - PPP 03-May-2020 Completed Clinical Trials - General
4. Later Stage VC (Series C) 30-Mar-2017 Completed Clinical Trials - General
3. Early Stage VC (Series B) 03-Feb-2016 Completed Clinical Trials - General
2. Early Stage VC (Series A) 06-Jun-2013 $20M $20M Completed Clinical Trials - General
1. Accelerator/Incubator Completed Clinical Trials - General
To view OrphAI Therapeutics’s complete valuation and funding history, request access »

OrphAI Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B 12,500,000 $0.000100 8% $0.8 $0.8 1x $0.8 5.58%
Series A 25,250,000 $0.000100 8% $0.8 $0.8 1x $0.8 11.28%
To view OrphAI Therapeutics’s complete cap table history, request access »

OrphAI Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a precision therapeutics technology designed to treat cancer and rare diseases. The company's technology ac
Drug Discovery
New Haven, CT
16 As of 2022

South San Francisco, CA
 

Irvine, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OrphAI Therapeutics Competitors (34)

One of OrphAI Therapeutics’s 34 competitors is Genentech, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genentech Formerly VC-backed South San Francisco, CA
Seragon Formerly VC-backed Irvine, CA
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Merck & Co. Corporation Rahway, NJ
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 34 competitors. Get the full list »

OrphAI Therapeutics Patents

OrphAI Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11967436-B2 Methods and apparatus for making biological predictions using a trained multi-modal statistical model Active 30-May-2018
US-20200350081-A9 Methods and apparatus for making biological predictions using a trained multi-modal statistical model Active 30-May-2018
WO-2019067666-A1 Therapeutic methods relating to hsp90 inhbitors Inactive 27-Sep-2017
WO-2018144680-A1 Methods for treating cancer using hsp90 inhibitors Inactive 03-Feb-2017
WO-2018071548-A1 Apilimod compositions and methods for using same in the treatment of alzheimer's disease Inactive 12-Oct-2016 A61K31/5377
To view OrphAI Therapeutics’s complete patent history, request access »

OrphAI Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OrphAI Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
4Catalyzer Accelerator/Incubator Minority
Albany Capital (Australia) Venture Capital Minority
Gravity Ventures (Korea) Corporate Venture Capital Minority
LifeSci Venture Partners Corporate Venture Capital Minority
Shenzhen Sangel Venture Capital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

OrphAI Therapeutics FAQs

  • When was OrphAI Therapeutics founded?

    OrphAI Therapeutics was founded in 2013.

  • Where is OrphAI Therapeutics headquartered?

    OrphAI Therapeutics is headquartered in New Haven, CT.

  • What is the size of OrphAI Therapeutics?

    OrphAI Therapeutics has 16 total employees.

  • What industry is OrphAI Therapeutics in?

    OrphAI Therapeutics’s primary industry is Drug Discovery.

  • Is OrphAI Therapeutics a private or public company?

    OrphAI Therapeutics is a Private company.

  • What is the current valuation of OrphAI Therapeutics?

    The current valuation of OrphAI Therapeutics is .

  • What is OrphAI Therapeutics’s current revenue?

    The current revenue for OrphAI Therapeutics is .

  • How much funding has OrphAI Therapeutics raised over time?

    OrphAI Therapeutics has raised $154M.

  • Who are OrphAI Therapeutics’s investors?

    4Catalyzer, Albany Capital (Australia), Gravity Ventures (Korea), LifeSci Venture Partners, and Shenzhen Sangel Venture Capital are 5 of 8 investors who have invested in OrphAI Therapeutics.

  • Who are OrphAI Therapeutics’s competitors?

    Genentech, Seragon, Renova Therapeutics, Merck & Co., and Inovio Pharmaceuticals are some of the 34 competitors of OrphAI Therapeutics.

  • When was OrphAI Therapeutics acquired?

    OrphAI Therapeutics was acquired on 18-May-2026.

  • Who acquired OrphAI Therapeutics?

    OrphAI Therapeutics was acquired by IRulya Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process